← Leaderboards
Maya Fayfman
Emory University
$1,339,223
Attributed
$1,616,740
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $555K · FY2020–25$1M$750K$500K$250K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,616,740 · 3
By mechanism
K23$870,006 · 1
R01$555,034 · 1
R03$191,700 · 1
Top collaborators
- Marcos C. Schechter1 shared
Most similar at Emory University
Same institution · by research overlap
- Mohammed Kumail Ali$8,364,322
- Viswanathan Mohan$2,498,109
- Nicole Kristen Rendos$445,107
- Jean A. Welsh$1,925,640
- Erin Poe Ferranti$1,057,963
Others in their field
Other Emerging Leaders on “Randomized”
- Beth Baseler · Leidos Biomedical Research, Inc.$194,920,310
- Susan Abushakra · Alzheon, Inc.$50,765,244
- Susan M Landau · University Of California Berkeley$47,252,026
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$36,614,885
- Abraham Aizer Brody · New York University School Of Medicine$23,359,458
- Yunda Huang · Fred Hutchinson Cancer Center$19,033,873
Research focus
RandomizedHospitalizationGlycemic ControlComplexDiabetes ManagementDiabetes MellitusHospitalsProspective StudiesAdmission ActivityOralLength Of StayNon-Insulin-Dependent Diabetes MellitusHyperglycemiaPoint Of CareMentorsBlood GlucoseCostAdultGlucoseHealth EconomicsHypoglycemiaInsulinMortalityReporting
Grant awards (7)
Comprehensive Assistance and Resources for Effective Diabetic Foot Navigation (CARE-D-Foot-Nav), a randomized controlled trial$555,034
R01 · FY2025 · DK · contact PI
Use of Non-Insulin Agents in Hospitalized Patients with Type 2 diabetes (T2D)$167,907
K23 · FY2024 · DK · contact PI
Randomized controlled trial of continuous glucose monitoring compared to point of care glucose testing following hospital discharge on 12-week diabetic foot ulcer healing rates$191,700
R03 · FY2023 · DK · contact PI
Use of Non-Insulin Agents in Hospitalized Patients with Type 2 diabetes (T2D)$169,282
K23 · FY2023 · DK · contact PI
Use of Non-Insulin Agents in Hospitalized Patients with Type 2 diabetes (T2D)$177,118
K23 · FY2022 · DK · contact PI
Use of Non-Insulin Agents in Hospitalized Patients with Type 2 diabetes (T2D)$177,136
K23 · FY2021 · DK · contact PI
Use of Non-Insulin Agents in Hospitalized Patients with Type 2 diabetes (T2D)$178,563
K23 · FY2020 · DK · contact PI